PRESS RELEASE: REGULATED INFORMATION
Wednesday, 9 August 2017, 07:00 CEST
Invitation to the extraordinary shareholders’ meeting
Mechelen, Belgium, 9 August 2017 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, warrant holders, directors and statutory auditor to the extraordinary shareholders’ meeting that will be held on Monday 11 September 2017 at 10:00 a.m. CEST at the offices of the Company at Generaal de Wittelaan 11B, 2800 Mechelen, Belgium.
The agenda of the extraordinary shareholders’ meeting includes the proposed appointment of Herman Verrelst as director of the Company and approval of a new warrant plan for Herman Verrelst as the Chief Executive Officer of the Company. He will be taking up the role of Chief Executive Officer as from 1 September 2017.
In order to be admitted to the extraordinary shareholders’ meeting, the holders of securities issued by the Company must comply with Article 536 of the Belgian Companies Code and the articles of association of the Company, and fulfill the formalities described in the convening notice. The convening notice and other documents relating to the extraordinary shareholders’ meeting can be consulted on the website of the Company.
— END —
More information:
Renate Degrave
Manager Corporate Communications & Investor Relations Biocartis
email rdegrave@biocartis.com
tel +32 15 631 729 | mobile +32 471 53 60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis’ proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers ten oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.
The Biocartis trademark and logo are trademarks of Biocartis and are used and registered in Europe. Idylla(TM) is a registered trademark in the United States and other countries. The Idylla(TM) trademark and logo are trademarks of and used by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be prohibited by applicable law. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.
Forward-looking statements
This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to update or revise any forward-looking statements in this press release. You should not place undue reliance on forward-looking statements.
